Skip to main content
Premium Trial:

Request an Annual Quote

Cellzome, Graffinity Win $2.6M from German Gov t to Develop Immune System Treatments

NEW YORK, Oct. 12 (GenomeWeb News) - Cellzome and Graffinity, a unit of Santhera Pharmaceuticals, will receive €1.1 million ($1.3 million) each from the German Ministry of Research and Education to discover new treatments for immune system disorders, the Heidelberg, Germany-based companies said today.


Over the next two years, Graffinity will screen up to nine targets provided by Cellzome,

using its fragment-based screening platform. It will also use part of the funding to increase the sensitivity of its technology.Cellzome will make use of its proteomics platform to identify targets and to profile hits and leads resulting from the collaboration.


The aim of the project is to discover small molecule leads directed against several kinases in signalling pathways of the immune system.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.